• Textsize Middle
  • Textsize Large







Subject Urology
Professor: Osamu Ukimura 
Associate Professor: Fumiya Hongo,Masayoshi Okumi
Lecturer: Yasuyuki Naito, Astuko Fujihara
Assistant Professor: Takumi Shiraishi, Takashi Ueda,  Masatsugu Miyashita,
          Yuta Inoue, Jin Ajiki,Yumiko Saito
Research Contents
Department of Urology, Kyoto Prefectural University of Medicine
University Hospital, Kyoto Prefectural University of Medicine is located at the center of the Japanese-thousand-years ancient capital, Kyoto, Japan. It is a beautiful historical place between the Kamogawa River and the Kyoto Imperial Palace.  At the east side over the scenic Kamo River, we can see Mount Hiei and Daimonji in the Higashiyama Mountain range. The Department of Urology of Kyoto Prefectural University of Medicine, was established in 1964 and has a history spanning over 50 years. I joined our department 28 years ago and since then over 140 urological members have been active at affiliated hospitals in mainly Kyoto as well as Shiga, and Osaka prefecture. We cherish “love of humanity”, “dream” and “harmonious cooperation” and are involved with medical care, research and human resource development.  Under the staffs of our department who all are board certified urologists, a lot of talented young urologists are gathering to create their own dreams and future.
Outpatient Care
Urology is a special field covering the organs of the urinary tract (kidney, ureter, bladder and urethra) and the male reproductive system (prostate, testis and penis etc.) The diseases related to the adrenal gland and the retroperitoneum are also an object for urology. There are a variety of diseases in the field of urology, such as urological cancers (prostate cancer, renal cancer, urothelial cancer and testicular cancer etc.) and urinary dysfunction (benign prostate hyperplasia, overactive bladder and urinary incontinence etc.). Furthermore, urology also encompasses female urology, pediatric urology, male sexual dysfunction, male infertility, urinary infection and urinary stone. In our department, professional staffs in each fields can manage a wide range of urological diseases in specialty outpatient clinic. A woman doctor is always in charge of outpatient clinic for female urology.
Medical and Surgical Treatment
Urology is a part of surgery and our department can offer a variety of options including the state-of-the-art treatment as well as the standardized medicine and surgery while considering the efficacy, safety and invasiveness of treatment, and quality of life for patients. For examples, there are a lot of options such as robot assisted surgery, laparoscopic surgery, endoscopic surgery, highly difficult open surgery, urinary diversion, percutaneous cancer targeted therapy, new medical treatment, new function-sparing therapy, the latest radiation therapy, active surveillance and palliative care. We can provide accurate information in order for patients to select the best option in their own situations. I believe that patients’ proactive decision (adherence) is one of the most important keys that leads to the success of the treatment.
We have devoted ourselves to clinical and basic research in each specialized field, by which we have discovered innovative solutions to limitations of current medicine and newly emerged problems to be solved. As a consequence, we have discovered and reported the latest medical technology and the latest result of basic research, and made our best effort to internationally impact on the world. Our department can be characterized by our special environment and experience where we are able to conduct international exchange and collaborative research with foreign medical institutions.
  1. prostate biopsy using three-dimensional ultrasound-based organ-tracking technology: Initial experience in Japan.  Int J Urol. 2019 May;26(5):544-549.
  2. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Eur Urol. 2019 Feb;75(2):208-214.
  3. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?  J Urol. 2019 Feb;201(2):268-277.
  4. Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.Int J Urol. 2019 Feb;26(2):317-319.
  5. Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection.Medicine (Baltimore). 2018 Oct;97(42):e12740.
  6. Chemotherapy for metastatic testicular cancer: The first nationwide multi-institutional study by the Cancer Registration Committee of the Japanese Urological Association.  Int J Urol. 2018 Aug;25(8):730-736.
  7. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients.  Int J Urol. 2018 Jul;25(7):678-683.
  8. Probe-Based Confocal Laser Endomicroscopy Using Acrinol as a Novel Dye Can Be Used to Observe Cancer Nuclei of Bladder Carcinoma In Situ.  J Endourol Case Rep. 2018 Feb 1;4(1):25-27.
  9. Morphometric analysis of prostate zonal anatomy using magnetic resonance imaging: impact on age-related changes in patients in Japan and the USA.  BJU Int. 2017 Oct;120(4):497-504.
  10. Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses.  BMC Urol. 2017 Jan 18;17(1):10.
  11. Robotic transmural ablation of bladder tumors using high-intensity focused ultrasound: Experimental study.  Int J Urol. 2016 Jun;23(6):501-8.
  12. Personalized 3D printed model of kidney and tumor anatomy: a useful tool for patient education.  World J Urol. 2016 Mar;34(3):337-45.
  13. Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience.  World J Urol. 2016 Feb;34(2):221-7.
  14. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy.  Eur Urol. 2016 Jan;69(1):149-56.
  15. Three-dimensional Printed Model of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Nerve-sparing Prostatectomy.  Eur Urol. 2015 Sep
  16. Prostate Cancer Volume Estimation by Combining Magnetic Resonance Imaging and Targeted Biopsy Proven Cancer Core Length: Correlation with Cancer Volume.  J Urol. 2015 Oct;194(4):957-65.
  17. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel.  Prostate. 2015 Jun;75(8):863-71.
  18. Laparoendoscopic Single-site Surgery for Pediatric Urologic Disease.  J Endourol.
  19. Laparoscopic off-clamp partial nephrectomy using soft coagulation.  Int J Urol. 2015 Aug;22(8):731-4.
  20. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.  Int J Urol. 2015 Jul;22(7):663-8.
  21. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.  Int J Urol. 2015 Mar;22(3):288-93.
  22. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.  Brachytherapy. 2015 Mar-Apr;14(2):118-23.
  23. Experience of laparoscopic partial nephrectomy using a kidney grasper in selective cases.  J Laparoendosc Adv Surg Tech A. 2014 Nov;24(11):795-8.
  24. Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion.  Int J Clin Oncol. 2015 Jun;20(3):593-7.
  25. Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass.  Int J Clin Oncol. 2015 Apr;20(2):358-61.




  1. Preclinical orthotopic xenograft model of renal pelvis cancer in which cancer growth could be traced by an in vivo imaging system. Int J Urol. 2019 Jan;26(1):138-139.
  2. MRGBP promotes AR-mediated transactivation of KLK3 and TMPRSS2 via acetylation of histone H2A.Z in prostate cancer cells.  Biochim Biophys Acta Gene Regul Mech. 2018 Sep;1861 (9): 794-802
  3. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. Cancer Lett. 2018 Sep 1;431:182-189.
  4. CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells.  Oncotarget. 2018 Apr 3;9(25):17645-17655.
  5. Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.  Oncoimmunology. 2018 Feb 8;7(5)
  6. Disruption of circadian clockwork in in vivo reprogramming-induced mouse kidney tumors.  Genes Cells. 2018 Feb;23(2):60-69.
  7. FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.  Oncol Rep. 2018 Feb;39(2):627-632.
  8. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.  Biochem Biophys Res Commun. 2017 Apr 1;485(2):267-271.
  9. Identifying aggressive prostate cancer foci using a DNA methylation classifier.  Genome Biol. 2017 Jan 12;18(1):3.
  10. A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.  Mol Cancer Ther. 2016 Sep;15(9):2066-75.
  11. Androgen suppresses testicular cancer cell growth in vitro and in vivo.  Oncotarget. 2016 Jun 7;7(23):35224-32.
  12. PAX2 promoted prostate cancer cell invasion through transcriptional regulation of HGF in an in vitro model.  Biochim Biophys Acta. 2015 Nov;1852(11):2467-73.


tel 81-75-251-5595
fax 81-75-251-5598
e-mail uro1@koto.kpu-m.ac.jp
HP http://kpum-urology.com/

602-8566 Kyoto-shi, Kamigyo-ku Kajii-cho,
Kawaramachi-Hirokoji, JAPAN